Form 4: Ovid Therapeutics CEO Granted 890,000 Stock Options

Ovid Therapeutics' President and CEO, Margaret A. Alexander, was granted 890,000 employee stock options with an exercise price of $1.76.

Summary

• Margaret A. Alexander, President and CEO of Ovid Therapeutics Inc., was granted 890,000 employee stock options.
• The options have an exercise price of $1.76 per share.
• The grant date for these options was January 4, 2026.
• The options will expire on January 3, 2036.
• Vesting schedule dictates that 25% of the shares will vest on January 1, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter.
• Vesting is contingent upon Ms. Alexander's continued service to the company.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event (stock option grant). While not directly impacting immediate financial results, it is generally positive as it aligns management incentives with shareholder interests for long-term value creation. It does not contain any negative operational or financial news.

Positives

• The grant of stock options aligns the interests of the CEO with those of shareholders, incentivizing long-term company performance.
• The significant number of options (890,000 shares) demonstrates a substantial commitment to the CEO's continued leadership and contribution.

Risks

• The vesting of the stock options is subject to the reporting person's continued services through the specified dates, meaning the options could be forfeited if employment ceases.

Future Outlook

The vesting schedule for the granted stock options extends over several years, indicating an expectation of continued service from the President and CEO, Margaret A. Alexander, and a long-term incentive structure for her leadership.

Industry Context

The grant of stock options to a President and CEO is a standard practice in the biotechnology and pharmaceutical industry, serving as a key component of executive compensation packages designed to attract, retain, and motivate top talent by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• Executive stock option grants are a common form of compensation across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The specific size of the grant (890,000 options) and the exercise price of $1.76 would typically be evaluated against peer group compensation data and the company's market capitalization and performance, though such comparative data is not provided in this filing.
• The multi-year vesting schedule (25% after one year, then monthly over three years) is a standard approach to ensure long-term commitment and performance from executives, consistent with practices at comparable companies.

Related Party Transactions

• The grant of 890,000 employee stock options to Margaret A. Alexander, the President and CEO, constitutes a related party transaction as it involves compensation provided to a key executive.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the CEO's financial incentives with the long-term performance of the company, potentially benefiting shareholders through increased focus on value creation.
• Employees: While not directly impacting other employees, executive compensation practices can influence overall company culture and compensation strategies.

Next Steps

• The granted options will begin to vest on January 1, 2027, with subsequent monthly vesting installments.
• The reporting person may choose to exercise vested options at any time before the expiration date of January 3, 2036, subject to company policy and blackout periods.

Key Dates

Keywords

Ovid Therapeutics, OVID, stock options, executive compensation, Form 4, insider transaction, Margaret A. Alexander, CEO